Impact of nitrate therapy on the expression of caveolin-1 and its phosphorylated isoform in lungs in the model of monocrotaline induced pulmonary hypertension

Kmecova, Z.; Malikova, E.; Zsigmondova, B.; Radik, M.; Veteskova, J.; Marusakova, M.; Krenek, P.; Klimas, J.

doi:10.2478/afpuc-2018-0002

Abstract

Aim: Nitric oxide signalling pathway showed to be one of the crucial factors in the treatment and pathogenesis of pulmonary arterial hypertension. The aim of this study was to determine the effect of administration of inorganic nitrate, NaNO₃, on the expression of caveolin-1 and its phosphorylated isoform (pTyr14Cav-1) in lungs in the experimental model of monocrotaline induced pulmonary hypertension.

Methods: 10 weeks old male Wistar rats were subcutaneously injected with 60 mg/kg dose of monocrotaline (MCT) or vehicle (CON). Twelve days after the injection, part of the MCT group was receiving 0.3 mM NaNO₃ (MCT+N0.3) daily in the drinking water and rest was receiving 0.08% NaCl solution. Four weeks after MCT administration, the rats were sacrificed in CO₂. Protein expression in lungs was determined by western blot.

Results: We observed a significant decrease in the caveolin-1 expression and a significant shift towards the expression of pTyr14Cav-1 in the group treated with nitrate (p < 0.05).

Conclusion: NaNO₃ administration affected the expression of caveolin-1 and the ratio of its active (phosphorylated) isoform increased.

References

[1] Archer, S. L., Weir, E. K., & Wilkins, M. R. (2010). Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation, 121(18), 2045–2066. https://doi.org/10.1161/CIRCULATIONAHA.108.84770710.1161/CIRCULATIONAHA.108.847707
Search in Google Scholar Back to article
[2] Austin, E. D., Loyd, J. E., & Phillips, J. A. (1993). Heritable Pulmonary Arterial Hypertension. GeneReviews^®. University of Washington, Seattle. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/20301658
Search in Google Scholar Back to article
[3] Clapp, L. H., & Gurung, R. (2015). The mechanistic basis of prostacyclin and its stable analogues in pulmonary arterial hypertension: Role of membrane versus nuclear receptors. Prostaglandins & Other Lipid Mediators, 120, 56–71. https://doi.org/10.1016/j.prostaglandins.2015.04.00710.1016/j.prostaglandins.2015.04.007
Search in Google Scholar Back to article
[4] Fleming, I., & Busse, R. (1999). Signal transduction of eNOS activation. Cardiovascular Research, 43(3), 532–41. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/1069032510.1016/S0008-6363(99)00094-2
Search in Google Scholar Back to article
[5] Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., … Luis Zamorano, J. (2016). 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. European Heart Journal, 37(1), 67–119. https://doi.org/10.1093/eurheartj/ehv31710.1093/eurheartj/ehv31726320113
Search in Google Scholar Back to article
[6] Haga, S., Tsuchiya, H., Hirai, T., Hamano, T., Mimori, A., & Ishizaka, Y. (2015). A novel ACE2 activator reduces monocrotaline-induced pulmonary hypertension by suppressing the JAK/STAT and TGF-β cascades with restored caveolin-1 expression. Experimental Lung Research, 41(1), 21–31. https://doi.org/10.3109/01902148.2014.95914110.3109/01902148.2014.95914125275723
Search in Google Scholar Back to article
[7] Humbert, M., Sitbon, O., & Simonneau, G. (2004). Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 351(14), 1425–1436. https://doi.org/10.1056/NEJMra04029110.1056/NEJMra04029115459304
Search in Google Scholar Back to article
[8] Chen, Z., Bakhshi, F. R., Shajahan, A. N., Sharma, T., Mao, M., Trane, A., … Minshall, R. D. (2012). Nitric oxide-dependent Src activation and resultant caveolin-1 phosphorylation promote eNOS/caveolin-1 binding and eNOS inhibition. Molecular Biology of the Cell, 23(7), 1388–1398. https://doi.org/10.1091/mbc.E11-09-081110.1091/mbc.e11-09-0811331580422323292
Search in Google Scholar Back to article
[9] Chettimada, S., Yang, J., Moon, H., & Jin, Y. (2015). Caveolae, caveolin-1 and cavin-1: Emerging roles in pulmonary hypertension. World Journal of Respirology, 5(2), 126. https://doi.org/10.5320/wjr.v5.i2.12610.5320/wjr.v5.i2.126543809528529892
Search in Google Scholar Back to article
[10] Klinger, J. R., & Kadowitz, P. J. (2017). The Nitric Oxide Pathway in Pulmonary Vascular Disease. The American Journal of Cardiology, 120(8), S71–S79. https://doi.org/10.1016/j.amjcard.2017.06.01210.1016/j.amjcard.2017.06.01229025573
Search in Google Scholar Back to article
[11] Lai, Y.-C., Potoka, K. C., Champion, H. C., Mora, A. L., & Gladwin, M. T. (2014). Pulmonary arterial hypertension: the clinical syndrome. Circulation Research, 115(1), 115–30. https://doi.org/10.1161/CIRCRESAHA.115.30114610.1161/CIRCRESAHA.115.301146409668624951762
Search in Google Scholar Back to article
[12] Lundberg, J. O., Weitzberg, E., & Gladwin, M. T. (2008). The nitrate– nitrite–nitric oxide pathway in physiology and therapeutics. Nature Reviews Drug Discovery, 7(2), 156–167. https://doi.org/10.1038/nrd246610.1038/nrd246618167491
Search in Google Scholar Back to article
[13] Malikova, E., Galkova, K., Vavrinec, P., Vavrincova-Yaghi, D., Kmecova, Z., Krenek, P., & Klimas, J. (2016). Local and systemic renin-angiotensin system participates in cardiopulmonary-renal interactions in monocrotaline-induced pulmonary hypertension in the rat. Molecular and Cellular Biochemistry, 418(1–2), 147–57. https://doi.org/10.1007/s11010-016-2740-z10.1007/s11010-016-2740-z27344167
Search in Google Scholar Back to article
[14] Mathew, R. (2011). Cell-specific dual role of caveolin-1 in pulmonary hypertension. Pulmonary Medicine, 2011, 573432. https://doi.org/10.1155/2011/57343210.1155/2011/573432310942221660237
Search in Google Scholar Back to article
[15] Mathew, R. (2014). Pathogenesis of pulmonary hypertension: a case for caveolin-1 and cell membrane integrity. American Journal of Physiology-Heart and Circulatory Physiology, 306(1), H15–H25. https://doi.org/10.1152/ajpheart.00266.201310.1152/ajpheart.00266.201324163076
Search in Google Scholar Back to article
[16] Mathew, R., Huang, J., Shah, M., Patel, K., Gewitz, M., & Sehgal, P. B. (2004). Disruption of Endothelial-Cell Caveolin-1α/Raft Scaffolding During Development of Monocrotaline-Induced Pulmonary Hypertension. Circulation, 110(11), 1499–1506. https://doi.org/10.1161/01.CIR.0000141576.39579.2310.1161/01.CIR.0000141576.39579.2315353500
Search in Google Scholar Back to article
[17] Montani, D., Chaumais, M.-C., Guignabert, C., Günther, S., Girerd, B., Jaïs, X., … Humbert, M. (2014). Targeted therapies in pulmonary arterial hypertension. Pharmacology & Therapeutics, 141(2), 172–191. https://doi.org/10.1016/j.pharmthera.2013.10.00210.1016/j.pharmthera.2013.10.00224134901
Search in Google Scholar Back to article
[18] Morrell, N. W. (2006). Pulmonary Hypertension Due to BMPR2 Mutation: A New Paradigm for Tissue Remodeling? Proceedings of the American Thoracic Society, 3(8), 680–686. https://doi.org/10.1513/pats.200605-118SF10.1513/pats.200605-118SF17065373
Search in Google Scholar Back to article
[19] Patel, H. H., Zhang, S., Murray, F., Suda, R. Y. S., Head, B. P., Yokoyama, U., … Insel, P. A. (2007). Increased smooth muscle cell expression of caveolin-1 and caveolae contribute to the pathophysiology of idiopathic pulmonary arterial hypertension. The FASEB Journal, 21(11), 2970–2979. https://doi.org/10.1096/fj.07-8424com10.1096/fj.07-8424com17470567
Search in Google Scholar Back to article
[20] Thenappan, T., & Weir, E. K. (2017). The Nitric Oxide Pathway—A Potential Target for Precision Medicine in Pulmonary Arterial Hypertension. The American Journal of Cardiology, 120(8), S69– S70. https://doi.org/10.1016/j.amjcard.2017.06.01110.1016/j.amjcard.2017.06.01129025572
Search in Google Scholar Back to article
[21] Wertz, J. W., & Bauer, P. M. (2008). Caveolin-1 regulates BMPRII localization and signaling in vascular smooth muscle cells. Biochemical and Biophysical Research Communications, 375(4), 557–561. https://doi.org/10.1016/J.BBRC.2008.08.06610.1016/j.bbrc.2008.08.06618725205
Search in Google Scholar Back to article
[22] Zhao, Y.-Y., Zhao, Y. D., Mirza, M. K., Huang, J. H., Potula, H.-H. S. K., Vogel, S. M., … Malik, A. B. (2009). Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration. The Journal of Clinical Investigation, 119(7), 2009–18. https://doi.org/10.1172/JCI3333810.1172/JCI33338270185119487814
Search in Google Scholar Back to article